Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

BioSyent to Present at the LD Micro VI Investor Conference

V.RX

TORONTO, ONTARIO--(Marketwired - Dec. 2, 2013) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) is pleased to announce that CEO René Goehrum will be making a presentation at the LD Micro VI Investor Conference at 9am (PT), December 4, 2013 at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Mr. Goehrum will provide an overview of the Company and its corporate activities.

The presentation will be webcast live and may be accessed by visiting the Investor Center at the www.biosyent.com website or at the following conference link http://wsw.com/webcast/ldmicro5/BIOYF. A replay of the webcast will be available for 365 days after the presentation date.

To view and listen to the CEO presentation commenting on the Third Quarter 2013 Financial Results released November 21, 2013, please visit the following link http://www.biosyent.com/q3/.

For a direct market quote (15 minutes delay) for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.

About BioSyent Inc.

Listed on the Toronto Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth oriented specialty pharmaceutical company which searches the globe to in-license or acquire innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients and supporting the healthcare professionals that treat them.

Once a product of interest has been found, BioSyent then acquires the exclusive rights to the product and manages it through the Canadian governmental regulatory approval process. Once approved, BioSyent markets the product throughout Canada.

At the date of this press release the Company had 13,571,195 shares issued and outstanding.

BioSyent Inc.
Mr. Rene C. Goehrum
President and CEO
(905) 206-0013
investors@biosyent.com
www.biosyent.com



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today